Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomi...

by Strand, Vibeke, Fiorentino, David, Hu, ChiaChi, Day, Robert M, Stevens, Randall M, Papp, Kim A
Published 2013

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

by Edwards, Christopher J, Blanco, Francisco J, Crowley, Jeffrey, Birbara, Charles A, Jaworski, Janusz, Aelion, Jacob, Stevens, Randall M, Vessey, Adele, Zhan, Xiaojiang, Bird, Paul
Published 2016

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

by Kavanaugh, Arthur, Mease, Philip J, Gomez-Reino, Juan J, Adebajo, Adewale O, Wollenhaupt, Jürgen, Gladman, Dafna D, Lespessailles, Eric, Hall, Stephen, Hochfeld, Marla, Hu, ChiaChi, Hough, Douglas, Stevens, Randall M, Schett, Georg
Published 2014

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers

by van der Velden, Jos L. J., Ye, Ying, Nolin, James D., Hoffman, Sidra M., Chapman, David G., Lahue, Karolyn G., Abdalla, Sarah, Chen, Peng, Liu, Yong, Bennett, Brydon, Khalil, Nasreen, Sutherland, Donna, Smith, William, Horan, Gerald, Assaf, Mahmoud, Horowitz, Zebulun, Chopra, Rajesh, Stevens, Randall M., Palmisano, Maria, Janssen-Heininger, Yvonne M. W., Schafer, Peter H.
Published 2016